Dr. Alejandra Gonzalez-Duarte, MD
National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico
Talk Title: Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
A.Gonzalez‑Duarte1, D. Adams2, W.D. O’Riordan3, C.-C. Yang4, M. Ueda5, A.V. Kristen6, I. Tournev7, H.H. Schmidt8, T. Coelho9, J.L. Berk10, K.-P. Lin11, G. Vita12, S. Attarian13, V. Plante‑Bordeneuve14, M.M. Mezei15, J.M. Campistol16, J. Buades17, T.H. Brannagan III18, B..J. Kim19, J. Oh20, Y. Parman21, Y. Sekijima22, P.N. Hawkins23, S.D. Solomon24, M. Polydefkis25, P.J. Dyck26, P.J. Gandhi27, S. Goyal27, J. Chen27, A.L. Strahs27, S.V. Nochur27, M.T. Sweetser27, P.P. Garg27, A.K. Vaishnaw27, J.A. Gollob27, and O.B. Suhr28
1National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico City; 2Assistance Publique–Hopitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre HospitalierUniversitaire (CHU) Bicetre, INSERM Unite 1195, Universite Paris-Sud, Le Kremlin-Bicetre, France; 3Department of Clinical Research, eStudySite, San Diego, CA; 4the Department of Neurology, National Taiwan University Hospital, Taiwan; 5Kumamoto University Hospital, Kumamoto , Japan; 6the Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 7University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria; 8Medizinische Klinik B fur Gastroenterologie und Hepatologie, Universitatsklinikum Munster, Munster, Germany; 9Hospital de Santo Antonio, Centro Hospitalar do Porto, Porto, Portugal; 10the Amyloidosis Center, Department of Medicine, Boston Medical Center, Boston, MA; 11the Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; 12the Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy; 13the Department of Neuromuscular Disorders and ALS, Hopital de la Timone, Marseille, France;14the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Creteil, France; 15the Departments of Neurology and Medicine, Vancouver General Hospital, Vancouver, BC, Canada; 16the Department of Nephrology, Hospital Clinic, Barcelona, Spain; 17the Balearic Islands Health Research Institute and Hospital Son Llatzer, Palma de Mallorca, Spain; 18the Department of Neurology, Columbia University, College of Physicians and Surgeons, New York; 19Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 20the Department of Neurology, Konkuk University Medical Center, Seoul, South Korea; 21the Department of Neurology, Istanbul University, Istanbul, Turkey; 22Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan; 23the Division of Medicine, University College London, London; 24Harvard Medical School, Boston, MA; 25Johns Hopkins Bayview Medical Center, Baltimore; 26the Department of Neurology, Mayo Clinic, Rochester, MN; 27Alnylam Pharmaceuticals, Cambridge, MA; 28and the Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
Presenter at the meeting:
Alejandra Gonzalez-Duarte, MD, National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico
Biography: Dr. González-Duarte is a Neurologist and Internist at Instituto Nacional de CienciasMédicas y Nutrición in Mexico City. She is Director of the Autonomic and Small Fiber Laboratory and coordinates a large cohort of patients with Amyloidosis.